Peptides have traditionally been perceived as poor drug candidates due to unfavorable
characteristics mainly regarding their pharmacokinetic behavior, including plasma stability …

Cyclic peptides extend the druggable target space due to their size, flexibility, and hydrogen-
bonding capacity. However, these properties impact also their passive membrane …

An increasing number of drug discovery programs concern compounds in the beyond rule of
5 (bRo5) chemical space, such as cyclic peptides, macrocycles, and degraders. Recent …

Cyclic peptides have received increasing attention over the recent years as potential
therapeutics for “undruggable” targets. One major obstacle is, however, their often relatively …

Recently, cyclic peptides have been considered breakthrough drugs because they can
interact with “undruggable” targets such as intracellular protein–protein interactions …

Passive membrane permeability is a fundamental challenge in the development of bioactive
macrocycles. To achieve this objective, chemists have resorted to various strategies, the …

Cyclic peptides have attracted attention as a promising pharmaceutical modality due to their
potential to selectively inhibit previously undruggable targets, such as intracellular protein …

Knowing solution structures of cyclic peptides is essential for predicting pharmacokinetic
properties for drug discovery. Here, we report the MacroConf dataset along with …

Cyclic peptides that exhibit biomembrane permeability provide a useful platform in the
development of peptide drugs. Here, the reaction characteristics and versatility of a novel …

Compounds beyond the rule-of-five are generating interest as they expand the molecular
toolbox for modulating targets previously considered “undruggable”. Macrocyclic peptides …